Citadel Advisors
AYTU icon

Citadel Advisors’s AYTU BioPharma AYTU Stock Holding History

Citadel Advisors’s Portfolio AYTU Stock Details AYTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-4,605
Closed -$17K – 14856
2022
Q3 		$17K Sell
4,605
-2,770
-38% -$21K ﹤0.01% 12125
2022
Q2 		$102K Buy
7,375
+2,855
+63% +$36.5K ﹤0.01% 11394
2022
Q1 		$98K Sell
4,520
-1,045
-19% -$26K ﹤0.01% 12300
2021
Q4 		$150K Buy
5,565
+3,661
+192% +$158K ﹤0.01% 12253
2021
Q3 		$110K Buy
1,904
+64
+3% +$4.8K ﹤0.01% 12753
2021
Q2 		$184K Buy
+1,840
New +$216K ﹤0.01% 12253

Other funds holding AYTU

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $588M AUM 182.75% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
CAM
Crown Advisors Management Larkspur, California $151M AUM 73.11% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PAP
Persistent Asset Partners Hong Kong $268M AUM 158.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors's AYTU Position: Q1 2026 in Review

Citadel Advisors increased its AYTU BioPharma (AYTU) stake by 137% in Q1 2026, buying an estimated $54.4K and bringing the position to 36,841 shares worth $101K. The position accounts for ﹤0.01% of the portfolio, ranked #12019.

Citadel Advisors first reported a position in AYTU in Q1 2018 and has held it in 17 quarters since. The position peaked at $500K in Q4 2020. 37 funds tracked by Wall St. Rank hold AYTU as of Q1 2026.

  • Citadel Advisors held 36,841 shares of AYTU BioPharma worth $101K as of Q1 2026.
  • Citadel Advisors bought 21,290 AYTU BioPharma shares in Q1 2026, an estimated $54.4K.
  • AYTU BioPharma made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #12019 holding.
  • Citadel Advisors first reported a position in AYTU BioPharma in Q1 2018 and has held it in 17 quarters since.
  • Citadel Advisors's AYTU BioPharma position peaked at $500K in Q4 2020.
  • 37 funds tracked by Wall St. Rank held AYTU BioPharma as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.